Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at the Immuno Series US Virtual meeting which will be held online, October 15-16, 2020. Personalis will present “Maximizing immunotherapy biomarker discovery with a multidimensional tumor immunogenomics platform,” featuring the Personalis universal cancer immunogenomics approach, ImmunoID NeXT
October 15, 2020
· 3 min read